Spots Global Cancer Trial Database for estrogen receptor positive
Every month we try and update this database with for estrogen receptor positive cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| The Ultrasound Study of Tamoxifen | NCT01582074 | Breast Neoplasm... | 30 Years - 70 Years | National Institutes of Health Clinical Center (CC) | ||
| Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC | NCT05191004 | Advanced Breast... Metastatic Brea... Breast Cancer Breast Carcinom... Cancer of the B... Cancer of Breas... Malignant Tumor... Breast Tumor | NUV-422 Fulvestrant | 18 Years - | Nuvation Bio Inc. | |
| Prospective Observational Study Evaluating Treatment Decision Impact of Prosigna® in Early Stage Breast Cancer Patients | NCT02625935 | Breast Cancer | - | NanoString Technologies, Inc. | ||
| 4EVER - Efficacy, Safety, Health Economics, Translational Research of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer | NCT01626222 | Metastatic Brea... | Exemestane Everolimus (RAD... | 18 Years - | Novartis | |
| Letrozole, Herceptin in Her2neu +, Estrogen Receptor [ER] and/or Progesterone Receptor [PR] Positive, MBC | NCT00134680 | Metastatic Brea... | Letrozole Trastuzumab | 18 Years - | Duke University | |
| Safety and Efficacy of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer | NCT01231659 | Postmenopausal ... Locally Advance... Metastatic Brea... | Everolimus Letrozole | 18 Years - | Novartis | |
| A Study of ARV-471 (PF-07850327) Plus Palbociclib Versus Letrozole Plus Palbociclib in Participants With Estrogen Receptor Positive, Human Epidermal Growth Factor Negative Advanced Breast Cancer | NCT05909397 | Breast Cancer | ARV-471 (PF-078... Palbociclib Letrozole Palbociclib | 18 Years - | Pfizer | |
| Phase II Trial of SAHA & Tamoxifen for Patients With Breast Cancer | NCT00365599 | Breast Cancer | suberoylanilide... tamoxifen citra... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer | NCT02202746 | Breast Cancer Metastatic Brea... MBC HER2 Positive HER2 Estrogen Recept... ER Triple Negative | Lucitanib | 18 Years - | Clovis Oncology, Inc. | |
| A Study of Ridaforolimus (MK-8669) in Combination With Dalotuzumab (MK-0646) Compared to Standard of Care Treatment in Estrogen Receptor Positive Breast Cancer Patients (MK-8669-041 AM3) | NCT01234857 | Breast Cancer | ridaforolimus +... exemestane ridaforolimus dalotuzumab | 18 Years - | Merck Sharp & Dohme LLC | |
| A Study of AC682 for the Treatment of Locally Advanced or Metastatic ER+ Breast Cancer | NCT05080842 | Breast Cancer | AC682 | 18 Years - | Accutar Biotechnology Inc | |
| 4EVER - Efficacy, Safety, Health Economics, Translational Research of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer | NCT01626222 | Metastatic Brea... | Exemestane Everolimus (RAD... | 18 Years - | Novartis | |
| Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer | NCT03042897 | Estrogen Recept... Obesity Progesterone Re... Stage I Uterine... Stage IA Uterin... Stage IB Uterin... | Dietary Interve... Exercise Interv... Laboratory Biom... Quality-of-Life... | 19 Years - | University of Southern California | |
| A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer | NCT01421472 | ER Positive, He... Triple Negative... | MM-121 Paclitaxel | 18 Years - | Merrimack Pharmaceuticals | |
| A Study of Ridaforolimus (MK-8669) in Combination With Dalotuzumab (MK-0646) Compared to Standard of Care Treatment in Estrogen Receptor Positive Breast Cancer Patients (MK-8669-041 AM3) | NCT01234857 | Breast Cancer | ridaforolimus +... exemestane ridaforolimus dalotuzumab | 18 Years - | Merck Sharp & Dohme LLC | |
| GS-5829 in Combination With Fulvestrant or Exemestane in Women With Advanced Estrogen Receptor Positive, HER2 Negative-Breast Cancer | NCT02983604 | Advanced Estrog... | GS-5829 Exemestane Fulvestrant | 18 Years - | Gilead Sciences | |
| Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer | NCT03042897 | Estrogen Recept... Obesity Progesterone Re... Stage I Uterine... Stage IA Uterin... Stage IB Uterin... | Dietary Interve... Exercise Interv... Laboratory Biom... Quality-of-Life... | 19 Years - | University of Southern California | |
| A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer | NCT05054374 | Breast Cancer Breast Cancer S... HER2-negative B... Solid Carcinoma MEK1 Gene Mutat... MEK2 Gene Mutat... Metastatic Brea... | Mirdametinib Fulvestrant | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Prospective Observational Study of Clinical Outcomes for the NanoString® Technologies Prosigna Gene Signature Assay | NCT01899079 | Breast Cancer | - | NanoString Technologies, Inc. | ||
| Lifestyle Intervention Study in Adjuvant Treatment of Early Breast Cancer | NCT00463489 | Breast Cancer | Lifestyle inter... Mail-based | - | Ontario Clinical Oncology Group (OCOG) | |
| Clinical Trial Assessing the Safety of Neoadjuvant Palbociclib in Combination With Endocrine Therapy | NCT05069038 | Breast Cancer | Palbociclib 125... | 19 Years - | University of Nebraska | |
| Alisertib and Fulvestrant in Treating Patients With Hormone Receptor Positive Breast Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery | NCT02219789 | Estrogen Recept... Progesterone Re... Recurrent Breas... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast... | Alisertib Fulvestrant Laboratory Biom... | 18 Years - | Mayo Clinic | |
| Anti-Tumor Immunity Induced by Cryoablation of Invasive Breast Cancers | NCT01856036 | Breast Cancer | Cryoablation | 18 Years - | Saint John's Cancer Institute | |
| A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer | NCT02202746 | Breast Cancer Metastatic Brea... MBC HER2 Positive HER2 Estrogen Recept... ER Triple Negative | Lucitanib | 18 Years - | Clovis Oncology, Inc. | |
| Study of the Effect of the Addition of SNDX-275 (Entinostat) to Continued Aromatase Inhibitor (AI) Therapy in Postmenopausal Women With ER+ Breast Cancer Whose Disease is Progressing | NCT00828854 | ER+ Breast Canc... | Entinostat Aromatase Inhib... | - | Syndax Pharmaceuticals | |
| Prospective Observational Study Evaluating Treatment Decision Impact of Prosigna® in Early Stage Breast Cancer Patients | NCT02625935 | Breast Cancer | - | NanoString Technologies, Inc. | ||
| Dose Optimization of Rosuvastatin in Early Stage and Metastatic Estrogen Receptor Positive Breast Cancer Patients on Endocrine Therapy | NCT02483871 | Breast Cancer | Rosuvastatin | - | Duke University | |
| The Ultrasound Study of Tamoxifen | NCT01582074 | Breast Neoplasm... | 30 Years - 70 Years | National Institutes of Health Clinical Center (CC) | ||
| Broccoli Sprout Extract in Treating Patients With Breast Cancer | NCT01753908 | Ductal Breast C... Ductal Breast C... Estrogen Recept... Estrogen Recept... Invasive Breast... Lobular Breast ... Postmenopausal Stage IA Breast... Stage IB Breast... Stage IIA Breas... Stage IIB Breas... | Broccoli Sprout... Laboratory Biom... Pharmacological... Placebo | 21 Years - | Roswell Park Cancer Institute | |
| Clinical Trial Assessing the Safety of Neoadjuvant Palbociclib in Combination With Endocrine Therapy | NCT05069038 | Breast Cancer | Palbociclib 125... | 19 Years - | University of Nebraska | |
| Study of the Effect of the Addition of SNDX-275 (Entinostat) to Continued Aromatase Inhibitor (AI) Therapy in Postmenopausal Women With ER+ Breast Cancer Whose Disease is Progressing | NCT00828854 | ER+ Breast Canc... | Entinostat Aromatase Inhib... | - | Syndax Pharmaceuticals | |
| Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC | NCT05191004 | Advanced Breast... Metastatic Brea... Breast Cancer Breast Carcinom... Cancer of the B... Cancer of Breas... Malignant Tumor... Breast Tumor | NUV-422 Fulvestrant | 18 Years - | Nuvation Bio Inc. | |
| Lapatinib and Tamoxifen in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Tamoxifen | NCT00118157 | Estrogen Recept... Male Breast Car... Progesterone Re... Recurrent Breas... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast... | Laboratory Biom... Lapatinib Ditos... Tamoxifen Citra... | 18 Years - | National Cancer Institute (NCI) | |
| Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through the Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast | NCT02993159 | Ductal Breast C... Estrogen Recept... | Afimoxifene Laboratory Biom... Placebo Placebo Tamoxifen Citra... | 18 Years - | Northwestern University | |
| AZD9496 First Time in Patients Ascending Dose Study | NCT02248090 | ER+ HER2- Advan... | AZD9496 AZD9496 | 18 Years - | AstraZeneca | |
| GS-5829 in Combination With Fulvestrant or Exemestane in Women With Advanced Estrogen Receptor Positive, HER2 Negative-Breast Cancer | NCT02983604 | Advanced Estrog... | GS-5829 Exemestane Fulvestrant | 18 Years - | Gilead Sciences | |
| Breast Cancer Diet Intervention Study | NCT03886389 | Early-stage Bre... Carbohydrate En... Proliferation Insulin Resista... Estrogen Recept... | PreOP | 25 Years - 100 Years | Helse Stavanger HF | |
| Safety, Feasibility and Efficacy of Vitamin D Supplementation in Women With Metastatic Breast Cancer (SAFE-D) | NCT02186015 | Adult Women Metastatic Brea... Estrogen Recept... | Cholecalciferol | 18 Years - | Loyola University | |
| F-18 FES PET/CT in Measuring Hormone Expression in Patients With Primary, Recurrent, or Metastatic Breast Cancer Undergoing Endocrine-Targeted Therapy | NCT02149173 | Estrogen Recept... Recurrent Breas... Stage IV Breast... | Computed Tomogr... Computed Tomogr... F-18 16 Alpha-F... Fludeoxyglucose... Laboratory Biom... Positron Emissi... Positron Emissi... | 18 Years - | University of Washington | |
| Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer | NCT02657928 | Estrogen Recept... Postmenopausal Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Recurrent Uteri... | Laboratory Biom... Letrozole Ribociclib | 18 Years - | Mayo Clinic | |
| Alisertib and Fulvestrant in Treating Patients With Hormone Receptor Positive Breast Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery | NCT02219789 | Estrogen Recept... Progesterone Re... Recurrent Breas... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast... | Alisertib Fulvestrant Laboratory Biom... | 18 Years - | Mayo Clinic | |
| Letrozole and Imatinib Mesylate in Treating Postmenopausal Participants With Estrogen or Progesterone Positive Metastatic Breast Cancer | NCT00338728 | Anatomic Stage ... Estrogen Recept... KIT Positive PDGFR Positive Postmenopausal Progesterone Re... Prognostic Stag... | Imatinib Mesyla... Letrozole | - | M.D. Anderson Cancer Center | |
| Efficacy of Tamoxifen Versus Toremifene in CYP2D6 IM/PM of Premenopausal Patients With ER-positive Early Breast Cancer | NCT03351062 | Breast Cancer F... | Tamoxifen Toremifene | 18 Years - 50 Years | Chinese Anti-Cancer Association | |
| A Study of ARV-471 (PF-07850327) Plus Palbociclib Versus Letrozole Plus Palbociclib in Participants With Estrogen Receptor Positive, Human Epidermal Growth Factor Negative Advanced Breast Cancer | NCT05909397 | Breast Cancer | ARV-471 (PF-078... Palbociclib Letrozole Palbociclib | 18 Years - | Pfizer | |
| Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy | NCT04692103 | Estrogen Recept... Primary or Recu... Stage IV Breast... | F-18 16 Alpha-F... Positron Emissi... Computed Tomogr... Fludeoxyglucose... Positron Emissi... Computed Tomogr... Laboratory Biom... | 18 Years - | University of Washington | |
| Study in Post-menopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer | NCT03176238 | Post Menopausal... | everolimus exemestane | 18 Years - | Novartis | |
| Study in Post-menopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer | NCT03176238 | Post Menopausal... | everolimus exemestane | 18 Years - | Novartis | |
| Prospective Observational Study Evaluating Treatment Decision Impact of Prosigna® in Early Stage Breast Cancer Patients | NCT02625935 | Breast Cancer | - | NanoString Technologies, Inc. | ||
| Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy | NCT00556374 | Breast Cancer | Placebo Denosumab Non-steroidal a... Zoledronic Acid Standard of Car... | 45 Years - 100 Years | Amgen | |
| Clinical Trial Assessing the Safety of Neoadjuvant Palbociclib in Combination With Endocrine Therapy | NCT05069038 | Breast Cancer | Palbociclib 125... | 19 Years - | University of Nebraska | |
| Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy | NCT04692103 | Estrogen Recept... Primary or Recu... Stage IV Breast... | F-18 16 Alpha-F... Positron Emissi... Computed Tomogr... Fludeoxyglucose... Positron Emissi... Computed Tomogr... Laboratory Biom... | 18 Years - | University of Washington | |
| AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast Cancer | NCT01597388 | Advanced Metast... | AZD2014 Fulvestrant | 18 Years - 100 Years | AstraZeneca | |
| Study in Post-menopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer | NCT03176238 | Post Menopausal... | everolimus exemestane | 18 Years - | Novartis | |
| AZD9496 First Time in Patients Ascending Dose Study | NCT02248090 | ER+ HER2- Advan... | AZD9496 AZD9496 | 18 Years - | AstraZeneca | |
| 4EVER - Efficacy, Safety, Health Economics, Translational Research of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer | NCT01626222 | Metastatic Brea... | Exemestane Everolimus (RAD... | 18 Years - | Novartis | |
| Breast Cancer Diet Intervention Study | NCT03886389 | Early-stage Bre... Carbohydrate En... Proliferation Insulin Resista... Estrogen Recept... | PreOP | 25 Years - 100 Years | Helse Stavanger HF | |
| A Prospective Observational Study of Clinical Outcomes for the NanoString® Technologies Prosigna Gene Signature Assay | NCT01899079 | Breast Cancer | - | NanoString Technologies, Inc. | ||
| Safety and Efficacy of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer | NCT01231659 | Postmenopausal ... Locally Advance... Metastatic Brea... | Everolimus Letrozole | 18 Years - | Novartis | |
| MK2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole and Fulvestrant in Treating Postmenopausal Women With Metastatic Breast Cancer | NCT01344031 | Estrogen Recept... Invasive Breast... Recurrent Breas... Stage IV Breast... | Akt Inhibitor M... Anastrozole Fulvestrant Laboratory Biom... | 18 Years - | National Cancer Institute (NCI) | |
| A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery | NCT05549505 | Breast Cancer | ARV-471 Anastrozole Surgical resect... | 18 Years - | Arvinas Inc. | |
| Study Of PF-04691502 (PI3K/mTOR Inhibitor) In Combination With Exemestane Compared With Exemestane Alone In Patients With Advanced Breast Cancer | NCT01658176 | Breast Neoplasm... | PF-04691502 Exemestane Exemestane | 18 Years - | Pfizer | |
| Accelerated Partial Breast Radiation Therapy Using High-Dose Rate Brachytherapy in Treating Patients With Early Stage Breast Cancer After Surgery | NCT02526498 | Ductal Breast C... Estrogen Recept... Invasive Breast... Progesterone Re... Stage IA Breast... Stage IB Breast... Stage IIA Breas... | Accelerated Par... High-Dose Rate ... Questionnaire A... | 45 Years - | Rutgers, The State University of New Jersey | |
| Exercise Intervention in Targeting Adiposity and Inflammation With Movement to Improve Prognosis in Breast Cancer | NCT03091842 | Cancer Survivor Central Obesity Estrogen Recept... Postmenopausal Progesterone Re... Stage I Breast ... Stage IA Breast... Stage IB Breast... Stage II Breast... Stage IIA Breas... Stage IIB Breas... Stage III Breas... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... | Exercise Interv... Exercise Interv... Exercise Interv... Informational I... Laboratory Biom... Quality-of-Life... Questionnaire A... | 18 Years - | University of Southern California | |
| Letrozole in Women With Advanced Estrogen/Progesterone Receptor Positive Uterine Leiomyosarcoma | NCT00856050 | Leiomyosarcoma | letrozole | 18 Years - | Dana-Farber Cancer Institute | |
| Anti-Tumor Immunity Induced by Cryoablation of Invasive Breast Cancers | NCT01856036 | Breast Cancer | Cryoablation | 18 Years - | Saint John's Cancer Institute | |
| GS-5829 in Combination With Fulvestrant or Exemestane in Women With Advanced Estrogen Receptor Positive, HER2 Negative-Breast Cancer | NCT02983604 | Advanced Estrog... | GS-5829 Exemestane Fulvestrant | 18 Years - | Gilead Sciences | |
| Lifestyle Intervention Study in Adjuvant Treatment of Early Breast Cancer | NCT00463489 | Breast Cancer | Lifestyle inter... Mail-based | - | Ontario Clinical Oncology Group (OCOG) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
